Rb loss has been shown to have synthetic lethality with aurora kinase deficiency, and cancer cells developing RB loss after CDK4/6 inhibition were recently found to be sensitive to a selective aurora kinase A inhibitor [145]. The gene discussed is CDK4; the disease is cancer.